Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).
Authors
Le Péchoux, CLaplanche, A
Faivre-Finn, Corinne
Ciuleanu, T
Wanders, R
Lerouge, D
Keus, R
Hatton, M
Videtic, G M
Senan, S
Wolfson, A
Jones, R
Arriagada, R
Quoix, E
Dunant, A
Affiliation
Radiation Oncology Department, Institut Gustave-Roussy, Villejuif, France.Issue Date
2011-05
Metadata
Show full item recordAbstract
We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL).Citation
Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). 2011, 22 (5):1154-63 Ann. Oncol.Journal
Annals of OncologyDOI
10.1093/annonc/mdq576PubMed ID
21139020Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdq576